Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Total Current Liabilities (2016 - 2025)

Vanda Pharmaceuticals' Total Current Liabilities history spans 16 years, with the latest figure at $145.2 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 45.19% year-over-year to $145.2 million; the TTM value through Dec 2025 reached $145.2 million, up 45.19%, while the annual FY2025 figure was $145.2 million, 45.19% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $145.2 million at Vanda Pharmaceuticals, up from $117.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $145.2 million in Q4 2025 and bottomed at $61.8 million in Q1 2021.
  • The 5-year median for Total Current Liabilities is $91.1 million (2022), against an average of $93.1 million.
  • The largest annual shift saw Total Current Liabilities surged 46.87% in 2022 before it dropped 8.41% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $74.4 million in 2021, then increased by 22.87% to $91.4 million in 2022, then fell by 4.09% to $87.7 million in 2023, then rose by 14.01% to $100.0 million in 2024, then skyrocketed by 45.19% to $145.2 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Total Current Liabilities are $145.2 million (Q4 2025), $117.9 million (Q3 2025), and $121.5 million (Q2 2025).